Current concepts in the treatment of Adamantiades-Behçet's disease

Drugs of the Future

Volumn 34, Issue 9, 2009, Pages 749-763

  Bonitsis, N G ^a,b   Altenburg, A ^a,b   Krause, L ^a,b   Stache, T ^a   Zouboulis, C C ^a,b  

^a DESSAU MEDICAL CENTER   (Germany)

^b German Registry on Adamantiades Behçet's Disease   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ALPHA2A INTERFERON; AZATHIOPRINE; BENZATHINE PENICILLIN; BENZOCAINE; CHLORAMBUCIL; CHLORTETRACYCLINE; COLCHICINE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN; DAPSONE; DONTISOLON; DOXYCYCLINE; DYNEXAN; ETANERCEPT; GELICAINE; INFLIXIMAB; LIDOCAINE; METHOTREXATE; METHYLPREDNISOLONE; MYDRIATIC AGENT; ORABASE; PENTOXIFYLLINE; PLACEBO; PREDNISOLONE; REBAMIPIDE; SOLCOSERYL; SUCRALFATE; THALIDOMIDE; TRIAMCINOLONE; TRIAMCINOLONE ACETONIDE; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; UNCLASSIFIED DRUG; UNINDEXED DRUG; ZENDIUM;

ADD ON THERAPY; APHTHOUS ULCER; ARTHRITIS; BEHCET DISEASE; CLINICAL TRIAL; DIET THERAPY; DRUG CONTRAINDICATION; DRUG DOSE REDUCTION; DRUG MECHANISM; DRUG TOLERABILITY; DRUG WITHDRAWAL; ERYTHEMA NODOSUM; FOLLICULITIS; GASTROINTESTINAL SYMPTOM; GENITAL ULCER; GINGIVA HYPERPLASIA; HEMORRHAGIC CYSTITIS; HUMAN; HYPERTENSION; LOW DRUG DOSE; LUNG FIBROSIS; MOUTH ULCER; NEPHROTOXICITY; NEUROLOGIC DISEASE; PAIN; PUSTULE; QUALITY OF LIFE; RETINA VASCULITIS; REVIEW; SENSORY NEUROPATHY; SURGICAL TECHNIQUE; UNSPECIFIED SIDE EFFECT; UVEITIS;

EID: 84930542019     PISSN: 03778282     EISSN: None     Source Type: Journal    
DOI: 10.1358/dof.2009.034.09.1424168     Document Type: Review

References (142)

1. Kalayciyan, A., Zouboulis, C.C. An update on Behçet's disease. J Eur Acad Dermatol Venereol 2007, 21(1): 1-10.
2. Zouboulis, C.C. Adamantiades-Behçet disease. In: Fitzpatrick's Dermatology in General Medicine, 7th Ed. Wolff, K., Goldsmith, L.A., Katz, S.I., Gilchrest, B.A., Paller, A.S., Leffell, D.J. (Eds.). McGraw Hill: New York/Chicago, 2008, 1620-6.
3. Zouboulis, C.C., Keitel, W. A historical review of early descriptions of Adamantiades-Behçet's disease. J Invest Dermatol 2002, 119(1): 201-5.
4. Altenburg, A., Papoutsis, N., Orawa, H., Martus, P., Krause, L., Zouboulis, C.C. Epidemiology and clinical manifestations of Adamantiades-Behçet disease in Germany - Current pathogenetic concepts and therapeutic possibilities. J Dtsch Dermatol Ges 2006, 4(1): 49-64.
5. Calamia, K.T., Wilson, F.C., Icen, M., Crowson, C.S., Gabriel, S.E., Kremers, H.M. Epidemiology and clinical characteristics of Behçet's disease in the US: A population-based study. Arthritis Rheum 2009, 61(5): 600-4.
6. Zouboulis, C.C., Turnbull, J.R., Martus, P. Univariate and multivariate analyses comparing demographic, genetic, clinical, and serological risk factors for severe Adamantiades-Behçet's disease. Adv Exp Med Biol 2003, 528: 123-6.
7. Krause, L., Köhler, A.-K., Altenburg, A. et al. Ocular involvement is associated with HLA-B51 in Adamantiades-Behçet's disease. Eye 2009, 23(5): 1182-6.
8. Zouboulis, C.C., Kötter, I., Djawari, D. et al. Current epidemiological data from the German Registry of Adamantiades-Behçet's Disease. Adv Exp Med Biol 2003, 528: 43-8.
9. Alpsoy, E., Donmez, L., Onder, M. et al. Clinical features and natural course of Behçet's disease in 661 cases: A multicentre study. Br J Dermatol 2007, 157(5): 901-6.
10. Silman, A.J. Criteria for diagnosis of Behçet's disease. Lancet 1990, 335(8697): 1078-80.
11. Alpsoy, E., Zouboulis, C.C., Ehrlich, G.E. Mucocutaneous lesions of Behcet's disease. Yonsei Med J 2007, 48(4): 573-85.
12. Zouboulis, C.C. Adamantiades-Behçet's disease. In: European Handbook of Dermatological Treatments, 2nd Ed. Katsambas, A.D., Lotti, T.M. (Eds.). Springer: Berlin/Heidelberg 2003, 16-26.
13. Zouboulis, C.C., Orfanos, C.E. Treatment of Adamantiades- Behçet's disease with systemic interferon alfa. Arch Dermatol 1998, 134(8): 1010-6.
14. Zouboulis, C.C. Morbus Adamantiades-Behçet. In: Ciclosporin in der Dermatologie. Mrowietz, U. (Ed.). Thieme: Stuttgart, 2003, 38-51.
15. Sfikakis, P.P., Markomichelakis, N., Alpsoy, E. et al. Anti-TNF therapy in the management of Behcet's disease-Review and basis for recommendations. Rheumatology (Oxford) 2007, 46(5): 736-41.
16. Hatemi, G., Silman, A., Bang, D. et al. EULAR recommendations for the management of Behçet disease. Ann Rheum Dis 2008, 67(12): 1656-62.
17. Altenburg, A., Abdel-Naser, M.B., Seeber, H., Abdallah, M., Zouboulis, C.C. Practical aspects of management of recurrent aphthous stomatitis. J Eur Acad Dermatol Venereol 2007, 21(8): 1019-26.
18. Chahine, L., Sempson, N., Wagoner, C. The effect of sodium lauryl sulfate on recurrent aphthous ulcers: A clinical study. Compend Contin Educ Dent 1997, 18(12): 1238-40.
19. Herlofson, B.B., Barkvoll, P. Sodium lauryl sulfate and recurrent aphthous ulcers. A preliminary study. Acta Odontol Scand 1994, 52(5): 257-9.
20. Kutcher, M.J., Ludlow, J.B., Samuelson, A.D., Campbell, T., Pusek, S.N. Evaluation of a bioadhesive device for the management of aphthous ulcers. J Am Dent Assoc 2001, 132(3): 368-76.
21. Saxen, M.A., Ambrosius, W.T., Rehemtula, al-K.F., Russell, A.L., Eckert, G.J. Sustained relief of oral aphthous ulcer pain from topical diclofenac in hyaluronan: A randomized, double-blind clinical trial. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 1997, 84(4): 356-61.
22. Skaare, A.B., Herlofson, B.B., Barkvoll, P. Mouthrinses containing triclosan reduce the incidence of recurrent aphthous ulcers (RAU). J Clin Periodontol 1996, 23(8): 778-81.
23. Edres, M.A., Scully, C., Gelbier, M. Use of proprietary agents to relieve recurrent aphthous stomatitis. Br Dent J 1997, 182(4): 144-6.
24. Ramos-e-Silva, M., Ferreira, A.F., Bibas, R., Carneiro, S. Clinical evaluation of fluid extract of Chamomillo recutita for oral aphthae. J Drugs Dermatol 2006, 5(7): 612-7.
25. Graykowski, E.A., Kingman, A. Double-blind trial of tetracycline in recurrent aphthous ulceration. J Oral Pathol 1978, 7(6): 376-82.
26. Henricsson, V., Axéll, T. Treatment of recurrent aphthous ulcers with aureomycin mouth rinse or Zendium dentifrice. Acta Odontol Scand 1985, 43(1): 47-52.
27. Gorsky, M., Epstein, J., Rabenstein, S., Elishoov, H., Yarom, N. Topical minocycline and tetracycline rinses in treatment of recurrent aphthous stomatitis: A randomized cross-over study. Dermatol Online J 2007, 13(2): 1.
28. Skulason, S., Holbrook, W.P., Kristmundsdottir, T. Clinical assessment of the effect of o matrix metalloproteinase inhibitor on aphthous ulcers. Acta Odontol Scand 2009, 67(1): 25-9.
29. Rattan, J., Schneider, M., Arber, N., Gorsky, M., Dayan, D. Sucralfate suspension as a treatment of recurrent aphthous stomatitis. J Intern Med 1994, 236(3): 341-3.
30. Alpsoy, E., Er, H., Durusoy, C., Yilmaz, E. The use of sucralfate suspension in the treatment of oral and genital ulceration of Behçet disease: A randomized, placebo-controlled, double-blind study. Arch Dermatol 1999, 135(5): 529-32.
31. Alidaee, M.R., Taheri, A., Mansoori, P., Ghodsi, S.Z. Silver nitrate cautery in aphthous stomatitis: A randomized controlled trial. Br J Dermatol 2005, 153(3): 521-5.
32. Lee, S.M., Lee, S.H. Generalized argyria after habitual use of AgN03. Dermatology 1994, 21(1): 50-3.
33. Collier, P.M., Neill, S.M., Copeman, R.W. Topical 5-aminosalicylic acid: A treatment for aphthous ulcers. Br J Dermatol 1992, 126(2): 185-8.
34. Fridh, G., Koch, G. Effect of a mouth rinse containing amylogiucosidase and glucose oxidase on recurrent aphthous ulcers in children and adolescents. Swed Dent J 1999, 23(2-3): 49-57.
35. Taylor, L.J., Walker, D.M., Bagg, J. A clinical trial of prostaglandin E2 in recurrent aphthous ulceration. Br Dent J 1993, 175(4): 125-9.
36. Ussher, M., West, R., Steptoe, A., McEwen, A. Increase in common cold symptoms and mouth ulcers following smoking cessation. Tob Control 2003, 12(1): 86-8.
37. Kalayciyan, A., Orawa, H., Fimmel, S. et al. Nicotine and biochanin A, but not cigarette smoke, induce anti-inflammatory effects on keratinocytes and endothelial cells in patients with Behçet's disease. J Invest Dermatol 2007, 127(1): 81-9.
38. Bittoun, R. Recurrent aphthous ulcers and nicotine. Med J Aust 1991, 154(7): 471-2.
39. Altenburg, A., Zouboulis, C.C. Current concepts in the treatment of recurrent aphthous stomatitis. Skin Therapy Lett 2008, 13(7): 1-4.
40. Mat, C., Yurdakul, S., Uysal, S. et al. A double-blind trial of depot corticosteroids in Behçet's syndrome. Rheumatology (Oxford) 2006, 45(3): 245-7.
41. Sharquie, K.E., Najim, R.A., Abu-Raghif, A.R. Dapsone in Behçet's disease: A double-blind, placebo-controlled, cross-over study. J Dermatol 2002, 29(5): 267-79.
42. Yurdakul, S., Mat, C., Tüzün, Y. et al. A double-blind trial of colchicine in Behçet's syndrome. Arthritis Rheum 2001, 44(11): 2686-92.
43. Joshi, A., Mamta. Behçet's syndrome with pyoderma-gangrenosum- like lesions treated successfully with dapsone monotherapy. J Dermatol 2004, 31(10): 806-10.
44. Fontes, V., Machet, L., Huttenberger, B., Lorette, G., Vaillant, L. Recurrent aphthous stomatitis: Treatment with colchicine. An open trial of 54 cases. Ann Dermatol Venereol 2002, 129(12): 1365-9.
45. Lee, K.Y., Kim do, Y., Chang, J.Y., Bang, D. Two cases of acute leukopenia induced by colchicine with concurrent immunosuppressants use in Behçet's disease. Yonsei Med J 2008, 49(1): 171-3.
46. Calgüneri, M., Ertenli, I., Kiraz, S., Erman, M., Celik, I. Effect of prophylactic benzathine penicillin on mucocutaneous symptoms of Behçet's disease. Dermatology 1996, 192(2): 125-8.
47. Al-Waiz, M.M., Sharquie, K.E., A-Qaissi, M.H., Hayani, R.K. Colchicine and benzathine penicillin in the treatment of Behçet disease: A case comparative study. Dermatol Online J 2005, 11(3): 3.
48. Matsuda, T., Ohno, S., Hirohata, S. et al. Efficacy of rebamipide as adjunctive therapy in the treatment of recurrent oral aphthous ulcers in patients with Behçet's disease: A randomised, double-blind, placebo-controlled study. Drugs 2003, 4(1): 19-28.
49. Liang, G.C., Chang, E.M. Pentoxifylline use for Behçet's disease. The result of a survey among rheumatologists in North America. Adv Exp Med Biol 2003, 528: 591-4.
50. Yasui, K., Ohta, K., Kobayashi, M., Aizawa, T., Komiyama, A. Successful treatment of Behçet disease with pentoxifylline. Ann Intern Med 1996, 124(10): 891-3.
51. Thornhill, M.H., Baccaglini, L., Theaker, E., Pemberton, M.N. A randomized, double-blind, placebo-controlled trial of pentoxifylline for the treatment of recurrent aphthous stomatitis. Arch Dermatol 2007, 143(4): 463-70.
52. Mimura, M.A., Hirota, S.K., Sugaya, N.N., Sanches, J.A. Jr., Migliari, D.A. Systemic treatment in severe cases of recurrent aphthous stomatitis: An open trial. Clinics (Sao Paulo) 2009, 64(3): 193-8.
53. Hamuryudan, V., Mat, C., Saip, S. et al. Thalidomide in the treatment of the mucocutaneous lesions of the Behçet syndrome. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 1998, 128(6): 443-50.
54. Bonnetblanc, J.M., Royer, C., Bedane, C. Thalidomide and recurrent aphthous stomatitis: A follow-up study. Dermatology 1996, 193(4): 321-3.
55. Grinspan, D. Significant response of oral aphthosis to thalidomide treatment. J Am Acad Dermatol 1985, 12(1, Pt. 1): 85-90.
56. Yazici, H., Pazarli, H., Barnes, C.G. et al. A controlled trial of azathioprine in Behçet's syndrome. N Engl J Med 1990, 322(5): 326-8.
57. Hamuryudan, V., Ozyazgan, Y., Hizli, N. et al. Azathioprine in Behcet's syndrome: Effects on long-term prognosis. Arthritis Rheum 1997, 40(4): 769-74.
58. Jorizzo, J.L., White, W.L., Wise, C.M., Zanolli, M.D., Sherertz, E.R Low-dose weekly methotrexate for unusual neutrophilic vascular reactions: Cutaneous polyarteritis nodosa and Behçet's disease. J Am Acad Dermatol 1991, 24(6, Pt. 2): 973-8.
59. Avci, O., Gürler, N., Günes, A.T. Efficacy of cyclosporine on mucocutaneous manifestations of Behçet's disease. J Am Acad Dermatol 1997, 36(5, Pt. 1): 796-7.
60. Masuda, K., Nakajima, A., Urayama, A., Nakae, K., Kogure, M., Inaba, G. Double-masked trial of cyclosporin versus colchicine and long-term open study of cyclosporin in Behçet's disease. Lancet 1989, 1(8647): 1093-6.
61. Zouboulis, C.C. Extended venous thrombosis in Adamantiades- Behçet's disease. Eur J Dermatol 2004, 14(4): 268-71.
62. Elliott, J.H., Ballinger, W.H. Behçet's syndrome: Treatment with chlorambucil. Trans Am Ophthalmol Soc 1984, 82: 264-81.
63. Kazokoglu, H., Saatçi, O., Cuhadaroglu, H., Eldem, B. Long-term effects of cyclophosphamide and colchicine treatment in Behçet's disease. Ann Ophthalmol 1991, 23(4): 148-51.
64. Kötter, I., Günaydin, I., Zierhut, M., Stübiger, N. The use of interferon alpha in Behçet disease: Review of the literature. Semin Arthritis Rheum 2004, 33(5): 320-35.
65. Alpsoy, E., Durusoy, C., Yilmaz, E., Ozgurel, Y., Ermis, O., Yazar, S., Basaran, E. Interferon alfa-2a in the treatment of Behçet disease: A randomized placebo-controlled and double-blind study. Arch Dermatol 2002, 138(4): 467-71.
66. Demiroglu, H., Ozcebe, O.I., Barista, I., Dündar, S., Eldem, B. Interferon alfa-2b, colchicine, and benzathine penicillin versus colchicine and benzathine penicillin in Behçet's disease: A randomised trial. Lancet 2000, 355(9204): 605-9.
67. Krause, L., Attenburg, A., Pleyer, U., Köhler, A.K., Zouboulis, C.C., Foerster, M.H. Longterm visual prognosis of patients with ocular Adamantiades-Behçet's disease treated with interferon-olpha-2a. J Rheumatol 2008, 35(5): 896-903.
68. Haugeberg, G., Velken, M., Johnson, V. Successful treatment of genital ulcers with infliximab in Behçet's disease. Ann Rheum Dis 2004, 63(6): 744-5.
69. Almoznino, G., Ben-Chetrit, E. Infliximab for the treatment of resistant oral ulcers in Behçet's disease: A case report and review of the literature. Clin Exp Rheumatol 2007, 25(Suppl. 4): S99-102.
70. Melikoglu, M., Fresko, I., Mat, C. et al. Short-term trial of etanercept in Behçet's disease: A double blind, placebo controlled study. J Rheumatol 2005, 32(1): 98-105.
71. Robinson, N.D., Guitart, J. Recalcitrant, recurrent aphthous stomatitis treated with etanercept. Arch Dermatol 2003, 139(10): 1259-62.
72. Sánchez-Cano, D., Callejas-Rubio, J.L., Ruiz-Villaverde, R., Ortego-Centeno, N. Recalcitrant, recurrent aphthous stomatitis successfully treated with adalimumab. J Eur Acad Dermatol Venereol 2009, 23(2): 206.
73. Vujevich, J., Zirwas, M. Treatment of severe, recalcitrant, major aphthous stomatitis with adalimumab. Cutis 2005, 76(2): 129-32.
74. Zouboulis, C.C. Epidemiology of Adamantiades-Behçet's disease. Ann Med Interne 1999, 150(6): 488-98.
75. Yazici, H., Barnes, C.G. Practical treatment recommendations for pharmacotherapy of Behçet's syndrome. Drugs 1991, 42(5): 796-804.
76. Bang, D. Treatment of Behçet's disease. Yonsei Med J 1997, 38(6): 401-10.
77. Hamdan, A., Mansour, W., Uthman, I., Masri, A.F., Nasr, F., Arayssi, T. Behcet's disease in Lebanon: Clinical profile, severity and two-decade comparison. Clin Rheumatol 2006, 25(3): 364-7.
78. Krause, L., Köhler, A.K., Altenburg, A. et al. Ocular involvement in Adamantiades-Behçefs disease in Berlin, Germany. Graefes Arch Clin Exp Ophthalmol 2009, 247(5): 661-6.
79. Davatchi, F., Shahram, F., Chams, C. et al. Recent epidemiological data on Behcet's disease in Iran. The 2001 survey. Adv Exp Med Biol 2003, 528: 31-6.
80. Tugal-Tutkun, I., Onal, S., Altan-Yaycioglu, R., Huseyin Altunbas, H., Urgancioglu, M. Uveitis in Behcet disease: An analysis of 880 patients. Am J Ophthalmol 2004, 138(2): 373-80.
81. Kötter, I., Vonthein, R., Muller, C.A., Gunaydin, I., Zierhut, M., Stubiger, N. Behcet's disease in patients of German and Turkish origin living in Germany: A comparative analysis. J Rheumatol 2004, 31(1): 133-9.
82. Torres, R.M., Yanez, B., Herreras, J.M., Calonge, M. Ocular Behcet disease. Retrospective study. Arch Soc Esp Oftalmol 2004, 79(12): 599-603.
83. Chung, Y.M., Yeh, T.S., Sheu, M.M., Chen, M.S., Wen, M.S., Tsai, H.Y., Liao, H.R. Behcet's disease with ocular involvement in Taiwan: A joint survey of six major ophthalmological departments. J Formos Med Assoc 1990, 89(5): 413-7.
84. Yoshida, A., Kawashima, H., Motoyama, Y. et al. Comparison of patients with Behcet's disease in the 1980s and 1990s. Ophthalmology 2004, 111(4): 810-5.
85. Kaktamani, V.G., Kaklamanis, P.G. Treatment of Behçet's disease - An update. Semin Arthritis Rheum 2001, 30(5): 299-312.
86. Toker, E., Kazokoglu, H., Acar, N. High dose intravenous steroid therapy for severe posterior segment uveitis in Behçet's disease. Br J Ophthalmol 2002, 86(5): 521-3.
87. Atmaca, L.S., Batioglu, F. The efficacy of cyclosporin A in the treatment of Behçet's disease. Ophthalmic Surg Lasers 1994, 25(5): 321-7.
88. Greenwood, A.J., Stanford, M.R., Graham, E.M. The role of azathioprine in the management of retinal vasculitis. Eye 1998, 12(Pt. 5): 783-8.
89. Mudun, B.A., Ergen, A., Ipcioglu, S.U., Burumcek, E.Y., Durlu, Y., Arslan, M.O. Short-term chlorambucil for refractory uveitis in Behçet's disease. Ocul Immunol lnflamm 2001, 9(4): 219-29.
90. O'Duffy, J.D., Robertson, D.M., Goldstein, N.P. Chlorambucil in the treatment of uveitis and meningoencephalitis of Behçet's disease. Am J Med 1984, 76(1): 75-84.
91. Ermakova, N.A. Comparative evaluation of the effectiveness of corticosteroids and cytostatics in treating retinal angiitis in Behçet's disease. Vestn Oftalmol 2002, 118(5): 32-5.
92. Kötter, I., Zierhut, M., Eckstein, A.K. et al. Human recombinant interferon alfa-2a for the treatment of Behçet's disease with sight threatening posterior or panuveitis. Br J Ophthalmol 2003, 87(4): 423-31.
93. Krause, L., Hoffmann, F., Zouboulis, C.C., Foerster, M.H. Vitrectomy and trabeculectomy combined with interferon alpha treatment in Adamantiades-Behçet's disease: A case report. Graefes Arch Clin Exp Ophthalmol 2003, 241(10): 871-4.
94. Wechsler, B., Bodaghi, B., Huong, D.L. et al. Efficacy of interferon alfa-2a in severe and refractory uveitis associated with Behçet's disease. Ocul Immunol lnflamm 2000, 8(4): 293-301.
95. Deuter, C.M., Kötter, I., Gunaydin, I., Zierhut, M., Stubiger, N. Ocular involvement in Behcet's disease: First 5-year-results for visual development after treatment with interferon alfa-2a. Ophthalmologe 2004, 101(2): 129-34.
96. Tugal-Tutkun, I., Guney-Tefekli, E., Urgancioglu, M. Results of interferon-alfa therapy in patients with Behcet uveitis. Graefes Arch Clin Exp Ophthalmol 2006, 244(12): 1692-5.
97. Bodaghi, B., Gendron, G., Wechsler, B. et al. Efficacy of interferon alpha in the treatment of refractory and sight threatening uveitis: A retrospective monocentric study of 45 patients. Br J Ophthalmol 2007, 91(3): 335-9.
98. Ohno, S., Nakamura, S., Hori, S. et al. Efficacy, safety and pharmacokinetics of multiple administration of infliximab in Behçet's disease with refractory uveoretinitis. J Rheumatol 2004, 31(7): 1362-8.
99. Theodossiades, P.G., Markomichelakis, N.N., Sfifkakis, P.P. Tumor necrosis factor antagonists: Preliminary evidence for an emerging approach in the treatment of ocular Inflammation. Retina 2007, 27(4): 399-413.
100. Elgin, U., Berker, N., Batman, A. Incidence of secondary glaucoma in Behcet disease. J Glaucoma 2004, 13(6): 441-4.
101. Özdemir, O., Erkam, N., Bakkaloglu, A. Results of pars plana vitrectomy in Behcet's disease. Ann Ophthalmol 1988, 20(1): 35-8.
102. Ozerturk, Y., Bardak, Y., Durmus, M. Vitreoretinal surgery in Behcet's disease with severe ocular complications. Acta Ophthalmol Scand 2001, 79(2): 192-6.
103. Krause, L., Altenburg, A., Bechrakis, N.E., Zouboulis, C.C., Foerster, M.H. Intraocular surgery under systemic interferon alpha therapy in ocular Adamantiades-Behçet's disease. Graefes Arch Clin Exp Ophthalmol 2007, 245(11): 1617-21.
104. Süllü, Y., Oge, I., Erkan, D. The results of cataract extraction and intraocular lens implantation in patients with Behcet's disease. Acta Ophthalmol Scand 2000, 78(6): 680-3.
105. Kadayifcilar, S., Gedik, S., Eldem, B., Irkec, M. Cataract surgery in patients with Behcet's disease. J Cataract Refract Surg 2002, 28(2): 316-20.
106. Matsuo, T., Takahashi, M., Inoue, Y., Egi, K., Kuwata, Y., Yamaoka, A. Ocular attacks after phacoemulsification and intraocular lens implantation in patients with Behcet disease. Ophthalmologica 2001, 215(3): 179-82.
107. Berker, N., Soykan, E., Elgin, U., Ozkan, S.S. Phacoemulsification cataract extraction and intraocular lens implantation in patients with Behcet's disease. Ophthalmic Surg Lasers Imaging 2004, 35(3): 215-8.
108. Hatachi, S., Nakazawa, T., Morinobu, A. et al. A pediatric patient with neuro-Behçet's disease. Mod Rheumatol 2006, 16(5): 321-3.
109. Appenzeller, S., de Castro, R., de Souza Queiroz, L. et al. Brain tumor-like lesion in Behçet disease. Rheumatol Int 2006, 26(6): 577-80.
110. Zouboulis, C.C., Kötter, I., Djawari, D. et al. Epidemiological features of Adamantiades-Behçet's disease in Germany and in Europe. Yonsei Med J 1997, 38(6): 411-22.
111. Kötter, I., Günaydin, I., Batra, M., Vontheim, R., Stübiger, N., Fierlbeck, G., Melms, A. CNS involvement occurs more frequently in patients with Behçet's disease under cyclosporin A (CSA) than under other medications -Results of a retrospective analysis of 117 cases. Clin Rheumatol 2006, 25(4): 482-6.
112. Altenburg, A., Köhler, A.K., Krause, L. et al. Effect of combination regimens and restrictions in the administration of TNF-antagonists in a patient with multisystemic, infliximab-refractory Adamantiades- Behçet's disease. EADV Conf (May 16-20, Austria) 2007, Poster presentation.
113. Krämer, M., Baumgärtel, M.W., Neuen-Jacob, E., Berlit, P. Myopathie beim Behçet-Syndrom. Z Rheumatol 2008, 67(3): 232-6.
114. Melillo, N., Sangle, S., Stanford, M.R., Andrews, T.C., D'Cruz, D.P. Low-dose intra-venous cyclophosphamide therapy in a patient with neurological complications of Behçet's disease. Clin Rheumatol 2007, 26(8): 1365-7.
115. Koçer, N., Istak, C., Siva, A., Saip, S., Akman, C., Kantarci, O., Hamuryudan, V. CNS involvement in neuro- Behçet-syndrome: An MR study. Am J Neuroradiol 1999, 20(6): 1015-24.
116. Pipitone, N., Olivieri, I., Cantini, F., Triolo, G., Salvarani, C. New approaches in the treatment of Adamantiades-Behçet's disease. Curr Opin Rheumatol 2006, 18(1): 3-9.
117. Boura, P., Tselios, K., Kamali, S., Skendros, P., Sarantopoulos, A., Topouzis, F. Concurrent relapsing central nervous system and ocular involvement in a case of life-threatening Adamantiades-Behçet disease (BD). Neurol Sci 2006, 27(6): 432-5.
118. Kurne, A., Arsava, E.M., Turkmen, I., Firat, M.M., Kansu, T. Extensive MRI lesion in brain stem of a neuro-Behcet patient. Eur J Neurol 2003, 10(3): 325-6.
119. Alty, J.E., Monaghan, T.M., Bamford, J.M. A patient with neuro-Behçet's disease is successfully treated with etanercept: Further evidence for the value of TNFalpha blockade. Clin Neurol Neurosurg 2007, 109(3): 279-81.
120. Erdem, H., Ding, A., Pay, S., Simsek, I., Uysal, Y. A neuro-Behçet's case complicated with intracranial hypertension successfully treated by a lumboperitoneal shunt. Joint Bone Spine 2006, 73(2): 200-1.
121. Al-Araji, A., Kidd, D.P. Neuro-Behçet's disease: Epidemiology, clinical characteristics, and management. Lancet Neurol 2009, 8(2): 192-204.
122. De Cata, A., Intiso, D., Bernal, M. et al. Prolonged remission of neuro-Behcet disease following autologous transplantation. Int J lmmunopathol Pharmacol 2007, 20(1): 91-6.
123. Ahn, J.K., Lee, Y.S., Jeon, C.H., Koh, E.M., Cha, H.S. Treatment of venous thrombosis associated with Behcet's disease: Immunosuppressive therapy alone versus immunosuppressive therapy plus anticoagulation Clin Rheumatol 2008, 27(2): 201-5.
124. Gurler, A., Boyvat, A., Tursen, U. Clinical manifestations of Behcet's disease: An analysis of 2147 patients. Yonsei Med J 1997, 38(6): 423-7.
125. Sarica-Kucukoglu, R., Akdag-Kose, A., Kayabal, I.M., Yazganoglu, K.D., Disci, R., Erzengin, D., Azizlerli, G. Vascular involvement in Behcet's disease: A retrospective analysis of 2319 cases. Int J Dermatol 2006, 45(8): 919-21.
126. Kural-Seyahi, E., Fresko, I., Seyahi, N. et al. The long-term mortality and morbidity of Behcet syndrome: A 2-decade outcome survey of 387 patients followed at a dedicated center. Medicine (Baltimore) 2003, 82(1): 60-76.
127. Hamuryudan, V., Er, T., Seyahi, E. et al. Pulmonary artery aneurysms in Behçet syndrome. Am J Med 2004, 117(11): 867-70.
128. Park, J.Y., Park, J.G., Won, J.H., Lee, J.M., Kim, N.S., Jung, T.H. Effects of corticosteroid and chlorambucil on multiple pulmonary artery aneurysms in Behcet's syndrome. A case report. J Korean Med Sci 1995, 10(6): 470-3.
129. Sakane, T., Takeno, M., Suzuki, N., Inaba, G. Current concepts - Behcet's disease. N Engl J Med 1999, 341(17): 1284-91.
130. Kobayashi, K., Ueno, F., Bito, S. et al. Development of consensus Statements for the diagnosis and management of intestinal Behçet's disease using a modified Delphi approach. J Gastroenterol 2007, 42(9): 737-45.
131. Brandt, L.J., Boley, S.J. Intestinal ischemia. In: Gastrointestinal and Liver Disease, 7th Ed. Feldman, M., Friedman, L.S., Sleisenger, M.H. (Eds.). Saunders: Philadelphia, 2002, 2321-40.
132. Pivetti-Pezzi, P., Accorinti, M., Abdulaziz, M.A., La Cava, M., Torella, M., Riso, D. Behçet's disease in children. Jpn J Ophthalmol 1995, 39(3): 309-14.
133. Kari, J.A., Shah, V., Dillon, M.J. Behçet's disease in UK children: Clinical features and treatment including thalidomide. Rheumatology 2001, 40(8): 933-8.
134. Uziel, Y., Brik, R., Padeh, S. et al. Juvenile Behçet's disease in Israel. Clin Exp Rheumatol 1998, 16(4): 502-5.
135. Kone-Paut, I., Yurdakul, S., Bahabri, S.A. et al. Clinical features of Behçet's disease in children: An international collaborative study of 86 cases. J Pediatr 1998, 132(4): 721-5.
136. Krause, I., Uziel, Y., Guedj, D. et al. Childhood Behçet's disease: Clinical features and comparison with adult-onset disease. Rheumatology 1999, 38(5): 457-62.
137. Evereklioglu, C. Current concepts in the etiology and treatment of Behçet's disease. Surv Ophthalmol 2005, 50(4): 297-350.
138. Yazici, H., Tuzun, Y., Pazarli, H. et al. Influence of age of onset and patient's sex on the prevalence and severity of manifestations of Behçet's syndrome. Ann Rheum Dis 1984, 43(6): 788-9.
139. Guillaume-Czitrom, S., Berger, C., Pajot, C., Bodaghi, B., Wechsler, B., Kone-Paut, I. Efficacy and safety of interferon alpha in the treatment of corticodependent uveitis of paediatric Behcet's disease. Rheumatology (Oxford) 2007, 46(10): 1570-3.
140. Ugras, M., Ertem, D., Celikel, C., Pehlivanoglu, E. Infliximab as an alternative treatment for Behçet disease when other therapies fail. J Pediatr Gastroenterol Nutr 2008, 46(2): 212-5.
141. Saulsbury, F.T., Mann, J.A. Treatment with infliximab for a child with Behçet's disease. Arthritis Rheum 2003, 49(4): 599-600.
142. Yasui, K., Uchida, N., Akazawa, Y., Nakamura, S., Minami, I., Amano, Y., Yamazaki, T. Thalidomide for treatment of intestinal involvement of juvenile-onset Behçet disease. Inflamm Bowel Dis 2008, 14(3): 396-400.